Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Global Health Network and the Family Larsson Rosenquist Foundation (FLRF) launch LactaHub: an open access knowledge platform featuring scientific and evidence-based information on breastfeeding and breastmilk for health professionals

Logos: TGHN and the Family Larsson Rosenquist Foundation

The Global Health Network and FLRF have created LactaHub to enable health professionals, decision-makers and researchers to be more effective in their daily work.

LactaHub is where scientific and evidence-based knowledge about breastfeeding and breastmilk will be brought together in a structured, practice-oriented manner. All content will be reviewed and verified for quality by an independent scientific editorial board, and made freely available.

LactaHub aims to become a thriving community of practice in the field of breastfeeding by:

  • Ensuring equal access to the best guidance and knowledge available, in one central location
  • Simplifying the search for objective information that has been independently verified
  • Opening new channels for knowledge transfer among health professionals – without physical or financial borders

Are you working in healthcare, policy or research with an interest in breastfeeding and the first 1,000 days? Learn more and please join the community

About The Global Health Network, of the University of Oxford

Faster and better research is critical to solving the world’s biggest health challenges. The Global Health Network enables researchers and organisations to share best practice and know-how with each other to drive progress, while empowering local health professionals undertaking research in the world’s most vulnerable settings. The Global Health Network facilitates sustainable health improvements through sharing of research methods, delivering training and supporting career development. The result is easier, faster, better research to help address the world's biggest health challenges.

About the Family Larsson Rosenquist Foundation

The Family Larsson-Rosenquist Foundation was established in 2013, born from the vision of a world in which every child is granted an optimum start in life through the benefits of breastmilk. Based in Frauenfeld, Switzerland, it is one of the world’s only philanthropic foundations dedicated entirely to supporting and promoting breastfeeding and breastmilk.

 

 

Similar stories

Risks of serious adverse events following treatment for visceral leishmaniasis

OCGHR Publication Research

This large-scale systematic review and meta-analysis aimed to collate all reported serious adverse events in visceral leishmaniasis clinical trials and quantify the incidence of mortality during the first 30 days of therapy. The analyses, which included clinical data from more than 35,000 patients, found that mortality following treatment was an extremely rare event and serious adverse events following treatments were poorly reported.

The RECOVERY Trial: One year on

OCGHR Research

The Randomised Evaluation of COVid-19 thERapY (RECOVERY) trial was officially launched on 23 March 2020. It is the world's largest COVID-19 drug trial. Thanks to the ground-breaking work of RECOVERY, clinicians treating patients hospitalised with severe COVID-19 now have two treatments that are known to improve survival.

Researchers call for access to Ivermectin for young children

OCGHR Publication Research

Millions of children weighing less than 15kg are currently denied access to Ivermectin treatment due to insufficient safety data being available to support a change to the current label indication. The WorldWide Antimalarial Resistance Network’s new meta-analysis provides evidence that supports removing this barrier and improving treatment equity.

Gender imbalance in visceral leishmaniasis clinical trials

OCGHR Publication Research

Researchers have found that despite an ongoing trend for a decreasing proportion of males being enrolled in antileishmanial therapeutic efficacy trials over time, there are still 1.8 times as many males as females involved in clinical trials. A new systematic review and meta-analysis suggests that existing knowledge on drug efficacy is derived from a study population that is heavily skewed towards adult males. At the same time, substantially less is known about the optimal treatment response in female patients.

New report highlights growing concern of vaccine falsification

MORU OCGHR

The Medicine Quality Research Group has published a new Medical Product Quality Report focussing on increasing issues around substandard and falsified (SF) COVID-19 vaccines. With the implementation of the key innovations of COVID-19 vaccines, there have been growing numbers of reports of SF vaccines in the public domain. Given the vital role they will play in ending the pandemic and protecting the global population but severe issues with equitable access, SF vaccines are highly likely to be a growing problem.

RECOVERY trial closes recruitment to colchicine treatment for patients hospitalised with COVID-19

OCGHR Research

Established to test a range of potential treatments for COVID-19, the RECOVERY trial has included a comparison of colchicine, an anti-inflammatory drug that is commonly used to treat gout, vs. usual care alone. There has been no convincing evidence of the effect of colchicine on clinical outcomes in patients admitted to hospital with COVID-19, and recruitment to the colchicine arm of the RECOVERY trial has now closed. Recruitment to all other treatment arms – aspirin, baricitinib, Regeneron’s antibody cocktail, and dimethyl fumarate – continues as planned.